BidaskClub downgraded shares of The Medicines (NASDAQ:MDCO) from a buy rating to a hold rating in a research note released on Tuesday.

A number of other equities analysts also recently issued reports on MDCO. ValuEngine raised shares of The Medicines from a hold rating to a buy rating in a research note on Friday, July 6th. Zacks Investment Research raised shares of The Medicines from a sell rating to a hold rating in a research note on Wednesday, May 2nd. Citigroup raised their target price on shares of The Medicines from $40.00 to $50.00 and gave the company a buy rating in a research note on Monday, August 20th. Oppenheimer set a $50.00 target price on shares of The Medicines and gave the company a buy rating in a research note on Thursday, August 16th. Finally, B. Riley assumed coverage on shares of The Medicines in a research note on Thursday, June 7th. They set a buy rating and a $55.00 target price for the company. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The Medicines has a consensus rating of Buy and a consensus target price of $52.63.

MDCO stock opened at $39.40 on Tuesday. The Medicines has a 1 year low of $24.45 and a 1 year high of $41.57. The stock has a market capitalization of $2.87 billion, a P/E ratio of -4.69 and a beta of 0.75. The company has a quick ratio of 2.55, a current ratio of 2.60 and a debt-to-equity ratio of 31.23.

The Medicines (NASDAQ:MDCO) last released its quarterly earnings results on Wednesday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.00) by $0.30. The Medicines had a negative net margin of 668.93% and a negative return on equity of 394.33%. The company had revenue of $1.67 million during the quarter, compared to the consensus estimate of $7.20 million. During the same period in the prior year, the firm earned ($0.72) earnings per share. The Medicines’s revenue was down 84.6% on a year-over-year basis. equities analysts anticipate that The Medicines will post -2.51 earnings per share for the current fiscal year.

In other The Medicines news, CEO Clive Meanwell sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $36.07, for a total transaction of $1,803,500.00. Following the completion of the transaction, the chief executive officer now owns 402,034 shares of the company’s stock, valued at $14,501,366.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.29% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the company. OppenheimerFunds Inc. grew its holdings in shares of The Medicines by 0.3% during the second quarter. OppenheimerFunds Inc. now owns 707,160 shares of the company’s stock valued at $25,953,000 after buying an additional 1,777 shares during the last quarter. State of Wisconsin Investment Board grew its holdings in shares of The Medicines by 2.6% during the second quarter. State of Wisconsin Investment Board now owns 70,100 shares of the company’s stock valued at $2,573,000 after buying an additional 1,800 shares during the last quarter. Profund Advisors LLC grew its holdings in shares of The Medicines by 15.8% during the first quarter. Profund Advisors LLC now owns 14,146 shares of the company’s stock valued at $466,000 after buying an additional 1,932 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of The Medicines by 1.4% during the first quarter. Rhumbline Advisers now owns 158,499 shares of the company’s stock valued at $5,221,000 after buying an additional 2,139 shares during the last quarter. Finally, Aperio Group LLC grew its holdings in shares of The Medicines by 8.5% during the second quarter. Aperio Group LLC now owns 28,013 shares of the company’s stock valued at $1,028,000 after buying an additional 2,203 shares during the last quarter.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

Featured Article: Price to Earnings Ratio (PE)

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.